Jim Sesic

Company: Atara Biotherapeutics Inc.

Job title: Senior Vice President, Regulatory Affairs

Bio:

Jim Sesic, is a seasoned regulatory executive with over 20 years of experience across the pharmaceutical, biotech, and cell and gene therapy sectors. As Head of Regulatory Affairs at Atara, he leads global regulatory strategy. Previously, he was Executive Director at Amgen, where he built Regulatory CMC capabilities and led international expansion efforts. He has also held roles at Portola Pharmaceuticals and Grifols Biologics, with experience spanning regulatory compliance, quality, and supply chain. Jim holds a B.S. in International Business Administration from California State University, Los Angeles, and is a licensed Pharmacist Exemptee in California.

Seminars:

Panel Discussion: Evaluating the Future of Autologous & Allogeneic Therapies 11:30 am

Evaluating the autologous and allogeneic cell therapy space Identify the optimal approach to maximize therapeutic efficacy Consider patient safety by addressing challenges related to rejection and adverse immune responses in both autologous and allogeneic therapies Evaluate if autologous or allogeneic therapies are best for future autoimmune therapy personalizationRead more

day: Conference Day Two Pink Track

Overcoming Translational Roadblocks to Accelerate Allogeneic Therapies to Clinic 12:15 pm

Identify current roadblocks in the progression of allogeneic therapies to clinic Share actionable strategies to overcome translational and regulatory hurdles Highlight Atara Biotherapeutics’ ATA3219 targeting lupus to inform the next steps toward market readinessRead more

day: Conference Day Two Pink Track

Panel Discussion: Re-Evaluating Lymphodepletion to Improve Patient Access & Limit Therapeutic Side Effects 9:00 am

Consider the need for lymphodepletion on cell therapy to identify opportunities to remove preconditioning from therapies Identify characteristics of therapies that avoid lymphodepletion to pinpoint opportunities to broaden their benefits to more therapies Examine the impact of lymphodepletion on patient recruitment and accessibilityRead more

day: Conference Day Two P1